• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥厚型梗阻性心肌病当代侵入性治疗方法综述及指南批判性评价:最新进展综述

Review of Contemporary Invasive Treatment Approaches and Critical Appraisal of Guidelines on Hypertrophic Obstructive Cardiomyopathy: State-of-the-Art Review.

作者信息

Lebowitz Steven, Kowalewski Mariusz, Raffa Giuseppe Maria, Chu Danny, Greco Matteo, Gandolfo Caterina, Mignosa Carmelo, Lorusso Roberto, Suwalski Piotr, Pilato Michele

机构信息

University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), 6200 MD Maastricht, The Netherlands.

出版信息

J Clin Med. 2022 Jun 14;11(12):3405. doi: 10.3390/jcm11123405.

DOI:10.3390/jcm11123405
PMID:35743475
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9225325/
Abstract

BACKGROUND

Hypertrophic obstructive cardiomyopathy (HOCM) is a heterogeneous disease with different clinical presentations, albeit producing similar dismal long-term outcomes if left untreated. Several approaches are available for the treatment of HOCM; e.g., alcohol septal ablation (ASA) and surgical myectomy (SM). The objectives of the current review were to (1) discuss the place of the standard invasive treatment modalities (ASA and SM) for HOCM; (2) summarize and compare novel techniques for the management of HOCM; (3) analyze current guidelines addressing HOCM management; and (4) offer suggestions for the treatment of complex HOCM presentations.

METHODS

We searched the literature and attempted to gather the most relevant and impactful available evidence on ASA, SM, and other invasive means of treatment of HOCM. The literature search yielded thousands of results, and 103 significant publications were ultimately included.

RESULTS

We critically analyzed available guidelines and provided context in the setting of patient selection for standard and novel treatment modalities. This review offers the most comprehensive analysis to-date of available invasive treatments for HOCM. These include the standard treatments, SM and ASA, as well as novel treatments such as dual-chamber pacing and radiofrequency catheter ablation. We also account for complex pathoanatomic presentations and current guidelines to offer suggestions for tailored care of patients with HOCM. Finally, we consider promising future therapies for HOCM.

CONCLUSIONS

HOCM is a heterogeneous disease associated with poor outcomes if left untreated. Several strategies for treatment of HOCM are available but patient selection for the procedure is crucial.

摘要

背景

肥厚型梗阻性心肌病(HOCM)是一种具有不同临床表现的异质性疾病,尽管未经治疗时会产生相似的不良长期预后。有几种方法可用于治疗HOCM;例如,酒精室间隔消融术(ASA)和外科室间隔心肌切除术(SM)。本综述的目的是:(1)讨论标准侵入性治疗方式(ASA和SM)在HOCM治疗中的地位;(2)总结和比较HOCM管理的新技术;(3)分析当前关于HOCM管理的指南;(4)为复杂HOCM表现的治疗提供建议。

方法

我们检索了文献,并试图收集关于ASA、SM和其他侵入性HOCM治疗方法的最相关且有影响力的现有证据。文献检索产生了数千条结果,最终纳入了103篇重要出版物。

结果

我们严格分析了现有指南,并在标准和新治疗方式的患者选择背景下提供了相关情况。本综述对目前可用的HOCM侵入性治疗进行了迄今为止最全面的分析。这些治疗包括标准治疗方法SM和ASA,以及双腔起搏和射频导管消融等新治疗方法。我们还考虑了复杂的病理解剖表现和当前指南,为HOCM患者的个性化护理提供建议。最后,我们考虑了HOCM未来有前景的治疗方法。

结论

HOCM是一种异质性疾病,若不治疗,预后较差。有几种治疗HOCM的策略,但手术的患者选择至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/349f4beb13e2/jcm-11-03405-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/15971b8b159f/jcm-11-03405-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/bd53be44c6e5/jcm-11-03405-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/63c82bd94fa0/jcm-11-03405-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/e26f1136ddfe/jcm-11-03405-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/2570aca33215/jcm-11-03405-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/a50f5b7c2556/jcm-11-03405-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/349f4beb13e2/jcm-11-03405-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/15971b8b159f/jcm-11-03405-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/bd53be44c6e5/jcm-11-03405-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/63c82bd94fa0/jcm-11-03405-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/e26f1136ddfe/jcm-11-03405-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/2570aca33215/jcm-11-03405-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/a50f5b7c2556/jcm-11-03405-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13b1/9225325/349f4beb13e2/jcm-11-03405-g007.jpg

相似文献

1
Review of Contemporary Invasive Treatment Approaches and Critical Appraisal of Guidelines on Hypertrophic Obstructive Cardiomyopathy: State-of-the-Art Review.肥厚型梗阻性心肌病当代侵入性治疗方法综述及指南批判性评价:最新进展综述
J Clin Med. 2022 Jun 14;11(12):3405. doi: 10.3390/jcm11123405.
2
Alcohol septal ablation: A useful tool in our arsenal against hypertrophic obstructive cardiomyopathy.酒精间隔消融术:我们对抗肥厚性梗阻性心肌病的有效手段。
J Card Surg. 2020 Aug;35(8):2017-2024. doi: 10.1111/jocs.14815. Epub 2020 Jul 11.
3
Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.酒精间隔消融术与室间隔心肌切除术治疗梗阻性肥厚型心肌病:一项系统评价和荟萃分析
J Clin Med. 2020 Sep 23;9(10):3062. doi: 10.3390/jcm9103062.
4
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.酒精间隔消融术治疗肥厚型梗阻性心肌病:已发表研究的系统评价
J Interv Cardiol. 2006 Aug;19(4):319-27. doi: 10.1111/j.1540-8183.2006.00153.x.
5
Predictors of long-term outcome after septal myectomy in symptomatic hypertrophic obstructive cardiomyopathy patients with previous alcohol septal ablation and residual obstruction.有症状的肥厚性梗阻性心肌病患者先前接受酒精室间隔消融术及存在残余梗阻后行室间隔心肌切除术的长期预后预测因素。
J Card Surg. 2019 Jul;34(7):533-540. doi: 10.1111/jocs.14072. Epub 2019 May 21.
6
Treating a Structural Heart Disease Using a Non-structural Approach: Role of Cardiac Pacing in Hypertrophic Cardiomyopathy.采用非结构性方法治疗结构性心脏病:心脏起搏在肥厚型心肌病中的作用
Cardiol Res. 2017 Feb;8(1):20-25. doi: 10.14740/cr512w. Epub 2017 Mar 3.
7
Is surgery the gold standard in the treatment of obstructive hypertrophic cardiomyopathy?手术是梗阻性肥厚型心肌病治疗的金标准吗?
Interact Cardiovasc Thorac Surg. 2013 Jan;16(1):5-9. doi: 10.1093/icvts/ivs352. Epub 2012 Sep 30.
8
[Long-term outcome of patients with hypertrophic obstructive cardiomyopathy post percutaneous transluminal septal ablation].肥厚性梗阻性心肌病患者经皮腔内室间隔消融术后的长期预后
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Apr 24;48(4):294-301. doi: 10.3760/cma.j.cn112148-20190603-00312.
9
Hypertrophic Obstructive Cardiomyopathy: Comparison of Outcomes After Myectomy or Alcohol Ablation.肥厚性梗阻性心肌病:心肌切除术或酒精消融术后结局的比较。
Front Cardiovasc Med. 2022 Mar 14;9:755376. doi: 10.3389/fcvm.2022.755376. eCollection 2022.
10
Two Hearts at Risk: Emergency Alcohol Septal Ablation in a Pregnant Woman With Decompensated HOCM.两颗心脏面临风险:一名失代偿性肥厚型梗阻性心肌病孕妇的紧急酒精间隔消融术
JACC Case Rep. 2020 Jan 15;2(1):139-144. doi: 10.1016/j.jaccas.2019.11.053. eCollection 2020 Jan.

引用本文的文献

1
Evaluation of myocardial structure and function in hypertrophic obstructive cardiomyopathy via cardiovascular magnetic resonance: regional distribution and sex differences.通过心血管磁共振评估肥厚型梗阻性心肌病的心肌结构和功能:区域分布及性别差异
Quant Imaging Med Surg. 2025 Sep 1;15(9):8594-8610. doi: 10.21037/qims-2025-457. Epub 2025 Aug 15.
2
The Utility of Nuclear Imaging in Hypertrophic Cardiomyopathy: A Narrative Review.核成像在肥厚型心肌病中的应用:一篇叙述性综述
J Clin Med. 2025 Mar 22;14(7):2183. doi: 10.3390/jcm14072183.
3
Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single-Center, Observational Study.

本文引用的文献

1
Septal Thickness Does Not Impact Outcome After Hypertrophic Obstructive Cardiomyopathy Surgery (Septal Myectomy and Subvalvular Mitral Apparatus Remodeling): A 15-Years of Experience.间隔厚度对肥厚性梗阻性心肌病手术(间隔心肌切除术和瓣膜下二尖瓣装置重塑)后的结果无影响:15年经验总结
Front Cardiovasc Med. 2022 Jun 15;9:853582. doi: 10.3389/fcvm.2022.853582. eCollection 2022.
2
Mechanical and interventional support for heart failure with preserved ejection fraction: A review.机械和介入支持治疗射血分数保留的心力衰竭:综述。
Artif Organs. 2022 Nov;46(11):2109-2117. doi: 10.1111/aor.14275. Epub 2022 May 17.
3
Effects of Metoprolol on Exercise Hemodynamics in Patients With Obstructive Hypertrophic Cardiomyopathy.
经皮心肌内射频消融治疗肥厚型心肌病的中期结果:单中心观察性研究。
J Am Heart Assoc. 2024 Aug 6;13(15):e034080. doi: 10.1161/JAHA.123.034080. Epub 2024 Jul 26.
4
A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy.肥厚型心肌病的现有和未来药物结构治疗的系统评价。
Clin Cardiol. 2024 Jan;47(1):e24207. doi: 10.1002/clc.24207.
5
Hypertrophic Cardiomyopathy-Current Challenges and Future Perspectives.肥厚型心肌病——当前挑战与未来展望
J Clin Med. 2023 Sep 21;12(18):6093. doi: 10.3390/jcm12186093.
6
Sudden cardiac death in the adolescent population: a narrative review.青少年人群中的心脏性猝死:一篇叙述性综述。
Egypt J Intern Med. 2023;35(1):36. doi: 10.1186/s43162-023-00222-3. Epub 2023 May 19.
7
A Narrative Review of Emerging Therapies for Hypertrophic Obstructive Cardiomyopathy.肥厚型梗阻性心肌病新兴治疗方法的叙述性综述。
Curr Cardiol Rev. 2023;19(4):e240323214927. doi: 10.2174/1573403X19666230324102828.
美托洛尔对梗阻性肥厚型心肌病患者运动血液动力学的影响。
J Am Coll Cardiol. 2022 Apr 26;79(16):1565-1575. doi: 10.1016/j.jacc.2022.02.024.
4
Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study.比索洛尔治疗有症状的梗阻性肥厚型心肌病患者。BASIC(比索洛尔治疗肥厚型心肌病)研究。
Int J Cardiol. 2022 May 1;354:22-28. doi: 10.1016/j.ijcard.2022.03.013. Epub 2022 Mar 10.
5
Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.随机试验米索洛尔治疗梗阻性肥厚型心肌病患者。
J Am Coll Cardiol. 2021 Dec 21;78(25):2505-2517. doi: 10.1016/j.jacc.2021.07.065.
6
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.2021年欧洲心脏病学会心脏起搏与心脏再同步治疗指南。
Eur Heart J. 2021 Sep 14;42(35):3427-3520. doi: 10.1093/eurheartj/ehab364.
7
Recurrent Takotsubo Cardiomyopathy in a Patient With Hypertrophic Cardiomyopathy Leading to Cardiogenic Shock Requiring VA-ECMO.肥厚型心肌病患者反复发生应激性心肌病致心源性休克需行体外膜肺氧合治疗
JACC Case Rep. 2020 Jun 17;2(7):1014-1018. doi: 10.1016/j.jaccas.2020.04.028.
8
Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial).随机对照试验显示,哌克昔林可使肥厚型心肌病(RESOLVE-HCM 试验)患者的左心室肥厚消退。
Am Heart J. 2021 Oct;240:101-113. doi: 10.1016/j.ahj.2021.06.010. Epub 2021 Jun 25.
9
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.VALOR-HCM 研究的设计和原理:评估马卡塞特在有症状的梗阻性肥厚型心肌病成人患者中的疗效,这些患者有资格接受间隔减少治疗。
Am Heart J. 2021 Sep;239:80-89. doi: 10.1016/j.ahj.2021.05.007. Epub 2021 May 24.
10
Durable mechanical circulatory support in patients with heart failure with preserved ejection fraction.心力衰竭射血分数保留患者的耐用性机械循环支持。
Interact Cardiovasc Thorac Surg. 2021 Oct 4;33(4):628-630. doi: 10.1093/icvts/ivab144.